24 November 2021 | News
"Gateway to Asia" Contract Manufacturing Organization (CMO) agreement to double volume of drugs produced for Amgen by Bushu Pharma
image credit- shutterstock
Bushu Pharmaceuticals has agreed on an expanded partnership with Amgen Inc. and Amgen K.K. to provide its "Gateway to Asia" service to four countries across the Asia-Pacific region as Amgen's contract manufacturing organization (CMO).
An integral factor in Amgen's business growth in Japan, Bushu Pharma has partnered with Amgen since 2016 to assure pharmaceutical drug product supply continuity and quality excellence for Amgen patients in Japan.
Further reinforcing the value of this partnership, Amgen has awarded Bushu Pharma the expanded Gateway to Asia contract for supply to Amgen's biggest markets, including mainland China, Taiwan and South Korea.
The decision is expected to double the current volume of Amgen products being manufactured and packaged by Bushu Pharma including Repatha, Evenity, Prolia, and Xgeva.
The scope of the work under Bushu Pharma's Gateway to Asia services will be to assemble, label, package and inspect the products for those markets, with the first supply of these drugs set to commence this year.